The higher frequency of KRAS mutations was clearly more evident (although not statistically significant) in cancers with a residual serrated adenoma (57.1%, 16/28), being observed twice as often as BRAF mutations (28.6%, 8/28). This evidence concerns the gene KRAS and cancer.